Business
Microbix Announces Fiscal 2005 Results: Year Highlighted By Sales Growth, Profitability, Infrastructure Investment And Acquisition Of A High-Value Technology
Microbix Announces Fiscal 2005 Results: Year Highlighted By Sales Growth, Profitability, Infrastructure Investment And Acquisition Of A High-Value Technology.
About this update from Microbix Biosystems Inc.
[{"type":"text","content":"\n\n\n\n\nTORONTO, Dec. 7 /CNW/ - Microbix Biosystems Inc. (MBX:TSX) today\nannounced financial results for the year ended September 30, 2005.\nMicrobix recorded record sales - up 8% on the year - even though the\nfourth quarter was down compared to a very strong performance in the same\nperiod a year earlier. Sales growth came from a solid core business,\ndevelopment contracts, and fees related to the Company's Vaccine Yield\nEnhancement Technology. Net profit for fiscal 2005 was $125,526 compared to\n$9,146 in fiscal 2004.\nThe strong financial results allowed the Company to continue its\nsignificant investments in manufacturing infrastructure and research and\ndevelopment, and to fund the acquisition of Sequent Biotechnologies Inc.\n(Sequent), a private company.\n\n>\n%SEDAR: 00004220E\n\n\n","length":4807,"tagName":"div"}]